 |
|
 |
|
|
|
|
 |
According to M100-S17 CLSI document there is interpretive criteia for colistin when testing Pseudomonas. Can I use these when testing Acinetobacter or should I continue with FDA guidelines and append the comment not CLSI standardized? If I connot use the interpretive criteria for Acinetobacter, should I use CLSI QC guidelines or continue using package insert FDA interps?
|
 |
I believe your question pertains to colistin disk diffusion for Acinetobacter spp. CLSI M100-S17 (2007) contains colistin disk interpretations for P. aeruginosa, but not for Acinetobacter. CLSI conducted further studies of colistin and polymyxin B in 2006, and found that colistin disk testing is reliable for P. aeruginosa isolates, but not for Acinetobacter because of false susceptible results. I would caution against using the P. aeruginosa colistin disk interpretations for Acinetobacter. CLSI recommends using an MIC method for colistin or polymyxin B for Acinetobacter.
DISCLAIMER
Askit is for general information purposes only and may not be relied upon by users for decisions or action in specific circumstances. Neither ASM nor the expert assures the accuracy or completeness of information provided. Questions are answered based on current information, which may change over time. Please note the date that a question was answered. If an answer is more than one year old, you may want to resubmit the question for an updated answer.
The advice and comments do not necessarily reflect the views of ASM. ASM and INDIVIDUAL experts expressly disclaim any and all liability for any direct, indirect, or special damages or loss of any nature incurred as a consequence of use of this site or any advice or comment by any expert. By using Askit, the user accepts the waiver of claims and all terms of use of ASM’s site, including the disclaimers set forth in the “Legal Rights” link on ASM’s home page.
|
| |
|
Return to Questions
|
|
|
|
 |
|
|
